RT Journal Article
SR Electronic
T1 Efficacy of propolis as an adjunct treatment for hospitalized COVID-19 patients: a randomized, controlled clinical trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.08.20248932
DO 10.1101/2021.01.08.20248932
A1 Duarte Silveira, Marcelo Augusto
A1 De Jong, David
A1 dos Santos Galvão, Erica Batista
A1 Ribeiro, Juliana Caldas
A1 Silva, Thiago Cerqueira
A1 Berretta, Andresa Aparecida
A1 Amorim, Thais Chaves
A1 San Martin, Raissa Lanna Araújo
A1 Rebelo da Conceição, Luis Filipe Miranda
A1 Dantas Gomes, Marcel Miranda
A1 Teixeira, Maurício Brito
A1 de Souza, Sergio Pinto
A1 Alves dos Santos, Marcele Helena Celestino
A1 de Oliveira Silva, Márcio
A1 Lírio, Monique
A1 Moreno, Lis
A1 Miranda Sampaio, Julio Cezar
A1 Mendonça, Renata
A1 Ultchak, Silviana Salles
A1 Amorim, Fabio Santos
A1 Rosa, João Gabriel
A1 Pena Batista, Paulo Benigno
A1 da Guarda, Suzete Nascimento Farias
A1 Mendes, Ana Verena Almeida
A1 Passos, Rogerio da Hora
A1 for the BeeCovid Team
YR 2021
UL http://medrxiv.org/content/early/2021/01/09/2021.01.08.20248932.abstract
AB Among candidate treatment options for COVID-19, propolis, produced by honey bees from bioactive plant exudates, has shown potential against viral targets and has demonstrated immunoregulatory properties. We conducted a randomized, controlled, open-label, single center trial, with a standardized propolis product (EPP-AF) on hospitalized adult COVID-19 patients. Patients received standard care plus propolis at an oral dose of 400mg/day (n=40) or 800mg/day (n=42) for seven days, or standard care alone (n=42). Standard care included all necessary interventions, as determined by the attending physician. The primary end point was the time to clinical improvement defined as the length of hospital stay or oxygen therapy dependency. Secondary outcomes included acute kidney injury and need for intensive care or vasoactive drugs. Time in the hospital after intervention was significantly shortened in both propolis groups compared to the controls; median 7 days with 400mg/day and 6 days with 800mg/day, versus 12 days for standard care alone. Propolis did not significantly affect the need for oxygen supplementation. With the higher dose, significantly fewer patients developed acute kidney injury than in the controls (2 versus 10 of 42 patients). Propolis as an adjunct treatment was safe and reduced hospitalization time. The registration number for this clinical trial is: NCT04480593 (20/07/2020).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04480593Funding StatementThe natural products company Apis Flora Indl. Coml. Ltda. in Ribeirao Preto, Sao Paulo, Brazil, provided funding and the propolis capsules for patient treatment. The D'Or Institute for Research and Education (IDOR) and Hospital Sao Rafael in Salvador, Bahia, Brazil, provided funding, infrastructure, and staff for assistance with the research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was approved by the Brazilian Committee of Ethics in Human Research (Registration number 31099320.6.0000.0048)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRelevant data is available in the manuscript file. If additional data is needed, it can be obtained from the Corresponding Author: Marcelo Augusto Duarte Silveira, MD, PhD, D'Or Institute for Research and Education (IDOR), Hospital Sao Rafael, Sao Rafael Avenue, 2152 - Sao Marcos, Salvador - Bahia, 41253-190, Brazil (marceloadsilveira@gmail.com)